ABSTRACT  Biliary-tract bloodstream infections (BT-BSI) caused by Enterococcus faecalis and E. faecium are associated with inappropriate empirical treatment and worse outcomes compared to other etiologies. The objective of this study was to investigate the risk factors for enterococcal BT-BSI. Patients with BT-BSI from the PROBAC cohort, including consecutive patients with BSI in 26 Spanish hospitals between October 2016 and March 2017, were selected; episodes caused by E. faecalis or E. faecium and other causes were compared. Independent predictors for enterococci were identified by logistic regression, and a predictive score was developed. Eight hundred fifty episodes of BT-BSI were included; 73 (8.5%) were due to target Enterococcus spp. (48 [66%] were E. faecium and 25 [34%] E. faecalis). By multivariate analysis, the variables independently associated with Enterococcus spp. were (OR; 95% confidence interval): cholangiocarcinoma (4.48;1.32 to 15.25), hospital acquisition (3.58;2.11 to 6.07), use of carbapenems in the previous month (3.35;1.45 to 7.78), biliary prosthesis (2.19;1.24 to 3.90), and moderate or severe chronic kidney disease (1.55;1.07 to 2.26). The AUC of the model was 0.74 [95% CI0.67 to 0.80].
score was developed, with 7, 6, 5, 4, and 2 points for these variables, respectively, with a negative predictive value of 95% for a score ≤ 6. A model, including cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous carbapenems, and chronic kidney disease showed moderate prediction ability for enterococcal BT-BSI. Although the score will need to be validated, this information may be useful for deciding empirical therapy in biliary tract infections when bacteremia is suspected.

**IMPORTANCE** Biliary tract infections are frequent, and a significant cause of morbidity and mortality. Bacteremia is common in these infections, particularly in the elderly and patients with cancer. Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis, and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci. This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms. To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score.

**KEYWORDS** bloodstream infection, *Enterococcus* spp., biliary tract infection

Biliary tract infections are frequent, and a significant cause of morbidity and mortality if not adequately treated (1). Bacteremia is common in these infections, particularly in the elderly and patients with cancer (2, 3). Although Gram-negative bacteria are the most frequent cause of these infections, enterococci cause 10 to 23% of bacteremic infections (2, 3). Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis (4, 5), and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci (4). This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms (6, 7). However, to the best of our knowledge, there is no studies identifying specific risk factors for covering enterococcal etiology in biliary tract infections.

The objectives of this study are to investigate the risk factors for *Enterococcus faecalis* and *Enterococcus faecium* bacteremic biliary tract infections and to develop a predictive score for this etiology. Our ultimate goal is to provide helpful information to guide empirical therapy in patients with biliary tract infections to improve coverage of enterococci when necessary, while avoiding the ecological impact and the possible side effects of overtreatment. In addition, we provide a detailed description of bacteremic biliary tract infections caused by these organisms.

**RESULTS**

Overall, 6313 episodes of bacteremia were included in the PROBAC cohort, and 850 (13.4%) had a biliary tract source. Among them, 73 (8.6%) were caused by the pathogens of interest, of which 48 were *E. faecium* (66%) and 25 *E. faecalis* (34%). Seven BT-BSI episodes caused by other enterococcal species (all of them were polymicrobial) were excluded; 5 were caused by *E. gallinarum* and by 2 *E. casseliflavus*.

Among the 73 included episodes of BT-BSI caused by enterococci, 37 (51%) were polymicrobial; the most frequent co-pathogens were *Escherichia coli* (14; 37.8%), *Klebsiella pneumoniae* (9; 24.3%), *K. oxytoca* (4; 10.8%), *Citrobacter freundii* (2; 5.4%), and *Enterobacter cloacae* (2; 5.4%).

The main demographic and clinical characteristics of patients with BT-BSI are described in Table 1. Their median age was 76 years; 313 (36.8%) were women and had a median age-adjusted Charlson index of 5. The most frequent comorbidities were cancer (252, 29.6%) and diabetes mellitus (212; 24.0%). Overall, 268 (31.5%) had biliary tract obstruction and 18% a biliary tract prosthesis; 201 (23.6%) had received antimicrobial therapy in the previous month. With regard to the severity of infection, 251 (20.5%) presented with severe sepsis or shock, and 344 (49.5%) had a SOFA score ≥2.

Regarding exposure to potential predisposing factors, BT-BSI due to enterococci were more frequently nosocomially acquired, the patients had a higher Charlson index, a higher
TABLE 1  Demographic, epidemiological, and baseline characteristics of bloodstream infections from a biliary tract source, and according to isolation of *Enterococcus faecalis* and *Enterococcus faecium* in blood cultures

| Variables | All patients n = 850 (%) | Isolation of *E. faecalis* or *E. faecium* (n = 73) | No isolation - others (n = 777) | P value |
|-----------|--------------------------|---------------------------------|--------------------------------|---------|
| Demographic |                           |                                 |                                |         |
| Median age in yrs (IQR) | 76 (65.84) | 75 (63-83) | 76 (66-84) | 0.11   |
| Female sex | 313 (36.8) | 29 (39.7) | 284 (775 (36.6) | 0.60   |
| Acquisition |                           |                                 |                                |         |
| Community acquired | 452 (53.2) | 22 (30.1) | 430 (55.4) | <0.001 |
| Community-onset, health-care related | 224 (26.4) | 16 (21.9) | 208 (26.8) | 0.36   |
| Hospital acquired | 173 (20.4) | 35 (47.9) | 138 (17.8) | <0.001 |
| Comorbidities |                           |                                 |                                |         |
| Median age-adjusted Charlson comorbidity index (IQR) | 5 (3-7) | 6 (4-8) | 5 (3-7) | 0.038 |
| Congestive heart failure | 68 (8.0) | 4 (5.5) | 64 (8.2) | 0.50   |
| Hypertension | 65 (7.6) | 6 (8.2) | 59 (7.6) | 0.84   |
| Dementia | 61 (7.2) | 6 (8.2) | 55 (7.1) | 0.71   |
| Cerebrovascular disease | 58 (6.8) | 4 (5.5) | 54 (6.9) | 0.27   |
| Chronic obstructive pulmonary disease | 90 (10.6) | 8 (11) | 82 (10.6) | 0.91   |
| Diabetes mellitus | 212 (24.9) | 18 (24.7) | 194 (25) | 0.95   |
| Diabetes mellitus with organ damage | 43 (5.1) | 5 (6.8) | 38 (4.9) | 0.40   |
| Moderate/severe liver disease | 83 (9.8) | 14 (19.2) | 69 (8.9) | 0.005  |
| Chronic kidney disease (stage 4-5) | 75 (8.8) | 11 (15.1) | 64 (8.2) | 0.04   |
| Connective tissue disorder | 18 (2.1) | 2 (2.7) | 16 (2.1) | 0.66   |
| Peptic ulcer | 22 (2.6) | 1 (4.5) | 21 (2.7) | 1.00   |
| Peripheral vascular disease | 57 (6.7) | 7 (9.6) | 60 (6.4) | 0.30   |
| Cancer | 252 (29.6) | 33 (45.2) | 219 (28.2) | 0.005  |
| Cholangiocarcinoma | 15 (1.8) | 6 (8.2) | 9 (1.2) | <0.001 |
| Pancreatic cancer | 13 (1.5) | 3 (4.1) | 10 (1.3) | 0.093  |
| Hematologic cancer | 18 (2.1) | 2 (2.7) | 16 (2.1) | 0.69   |
| Urinary obstruction | 9 (1.1) | 0 | 9 (1.2) | 1.00   |
| Recurrent urinary tract infection | 15 (1.8) | 3 (4.1) | 12 (1.5) | 0.11   |
| Biliary tract obstruction | 268 (31.5) | 27 (37) | 241 (31) | 0.29   |
| Immunosuppressive therapy | 67 (7.9) | 12 (16.4) | 55 (7.1) | 0.005  |
| Neutropenia <500 cells/μL | 12 (1.4) | 0 (0) | 12 (1.5) | 0.28   |
| Medical device and procedures |                           |                                 |                                |         |
| Biliary tract prosthesis | 153 (18) | 24 (32.9) | 129 (16.6) | 0.001  |
| Surgery (30 days before) | 48 (5.6) | 9 (12.3) | 39 (5) | 0.010  |
| Biliary surgery | 32 (3.8) | 7 (9.6) | 25 (3.2) | 0.006  |
| Parenteral feeding | 17 (2) | 5 (6.8) | 12 (1.5) | 0.002  |
| Esophagogastroduodenoscopy | 13 (1.5) | 2 (2.7) | 11 (1.4) | 0.30   |
| Endoscopic retrograde cholangiopancreatography | 5 (0.6) | 2 (2.7) | 3 (0.4) | 0.061  |
| Other upper gastrointestinal endoscopy | 50 (5.9) | 12 (16.4) | 38 (4.9) | <0.001 |
| Colonoscopy | 4 (0.5) | 0 | 4 (0.5) | 1.00   |
| Bronchoscopy | 34 (4) | 8 (11) | 26 (3.3) | 0.002  |
| Mechanical ventilation | 8 (0.9) | 4 (5.5) | 4 (0.5) | 0.003  |
| Previous antimicrobial treatment (30 days before) |                           |                                 |                                |         |
| Any antimicrobial | 201 (23.6) | 30 (41.4) | 171 (22) | <0.001 |
| Beta-lactam/beta-lactam inhibitor | 115 (13.5) | 20 (27.4) | 95 (12.2) | <0.001 |
| Carbapenem | 32 (3.8) | 11 (15.1) | 21 (2.7) | <0.001 |
| Third generation cephalosporin | 10 (1.2) | 9 (1.2) | 1 (1.4) | 0.87   |
| Severity at presentation |                           |                                 |                                |         |
| Sepsis and septic shock | 251 (29.5) | 28 (38.4) | 223 (28.7) | 0.084  |
| SOFA ≥ 2 | 344 (40.5) | 37 (50.7) | 307 (39.5) | 0.080  |
| Pitt score ≥ 3 | 60 (7.1) | 8 (13.3) | 52 (6.7) | 0.17   |
rate of moderate or severe liver disease, chronic kidney disease (stage 4 or 5) and cholangiocarcinoma, and more frequently had a biliary prosthesis and had undergone previous surgery, an endoscopic procedure and mechanical ventilation; also, they had more frequently received immunosuppressant drugs and antibiotics in the prior month, particularly beta-lactam/beta-lactam inhibitors and carbapenems (Table 2).

The multivariate analysis selected biliary prosthesis, cholangiocarcinoma, hospital acquisition, use of carbapenem in the previous 30 days and chronic kidney disease stage 4 or 5 as independent risk factors for enterococcal etiology (Table 2). The AUROC of the model for observed mortality was 0.74 (95% CI 0.67 to 0.80), indicating a moderate prediction ability. The NPV, PPV, sensibility and specificity for the different values of the score are showed in Table 3. A score value \( \geq 6 \) showed a NPV of 95% with a specificity of 80.4%; overall, the number of BT-BSI patients with a score <6 in our cohort were 657 (77.4%) and enterococci was isolated in 33 (5%) of them. On the other side, a score value \( \geq 10 \) (which were 58 [6.8%] of the BT-BSI population) showed a PPV of \( \geq 32.8\% \) (19 of them had *Enterococcus* spp. in blood cultures). When the score was applied to monomicrobial BSI due to *Enterococcus* spp., the AUC was 0.85 (95% CI 0.80 to 0.91); for monomicrobial *E. faecium*, the AUC was 0.87 (95% CI 0.81-0.93), and for monomicrobial *E. faecalis*, 0.75 (95% CI 0.60-0.81).

For a strictly descriptive interest, crude comparison of outcome data of enterococcal and other etiologies of BT-BSI are shown in Table 4. Overall, enterococcal BT-BSI in our cohort showed statistically significant higher proportions of inappropriate empirical therapy (43.8% versus 22.8%, \( P = 0.0002 \)), relapses (11.0% versus 4.6%, \( P = 0.02 \)) and secondary infections (4.1% versus 0.9%, \( P = 0.04 \)), and statistically nonsignificant,

### Table 2

| Variable                        | \( \beta \) coefficient | Or (95% CI)       | P value | Score |
|---------------------------------|-------------------------|-------------------|---------|-------|
| Cholangiocarcinoma              | 1.501                   | 4.48 (1.32-15.25) | 0.01    | +7    |
| Hospital acquisition            | 1.276                   | 3.58 (2.11–6.07)  | <0.001  | +6    |
| Carbapenem use in the previous mo | 1.211                   | 3.35 (1.45–7.78)  | 0.005   | +5    |
| Biliary prosthesis              | 0.785                   | 2.19 (1.24–3.90)  | 0.02    | +4    |
| Chronic kidney disease stage 4 or 5 | 0.441                   | 1.55 (1.07–2.26)  | 0.02    | +2    |

### Table 3

| Score points | VPP | VPN | Sensitivity | Specificity | No. of episodes | No. of faecalis and faecium infection |
|--------------|-----|-----|-------------|-------------|-----------------|--------------------------------------|
| 2            | 15.7 | 96.5 | 76.7        | 61.2        | 357             | 56                                   |
| 3            | 16.7 | 95.8 | 72.6        | 67.8        | 300             | 50                                   |
| 4            | 16.7 | 95.8 | 68.5        | 67.8        | 300             | 50                                   |
| 5            | 20.3 | 94.9 | 54.8        | 79.8        | 197             | 40                                   |
| 6            | 20.8 | 95.0 | 54.8        | 80.4        | 192             | 40                                   |
| 7            | 31.6 | 93.7 | 32.9        | 93.3        | 76              | 24                                   |
| 8            | 31.0 | 93.7 | 30.1        | 93.7        | 71              | 22                                   |
| 9            | 33.3 | 93.4 | 28.8        | 94.6        | 63              | 21                                   |
| 10           | 32.8 | 93.2 | 26          | 95.0        | 58              | 19                                   |
| 11           | 41.9 | 92.7 | 17.8        | 97.7        | 31              | 13                                   |
| 12           | 50.0 | 92.1 | 9.6         | 99.1        | 14              | 7                                    |
| 13           | 46.2 | 92.0 | 8.2         | 99.1        | 13              | 6                                    |
| 14           | 44.4 | 91.8 | 5.5         | 99.4        | 9               | 9                                    |
| 15           | 44.4 | 91.8 | 5.5         | 99.4        | 9               | 4                                    |
| 16           | 50.0 | 91.7 | 4.1         | 99.6        | 6               | 3                                    |
| 17           | 60   | 91.7 | 4.1         | 99.7        | 5               | 3                                    |
| 18           | 100  | 91.6 | 2.7         | 100         | 2               | 2                                    |
| 19           | 100  | 91.6 | 2.7         | 100         | 2               | 2                                    |
| 20           | 100  | 91.5 | 1.4         | 100         | 1               | 1                                    |
| 21           | 100  | 91.5 | 1.4         | 100         | 1               | 1                                    |
| 22           | 100  | 91.5 | 1.4         | 100         | 1               | 1                                    |
Numerically higher rates of mortality (21.9% versus 14.4%, \( P = 0.08 \)) and persistent bacteremia (5.5% versus 1.8%, \( P = 0.06 \)).

The empirical drugs received by patients with enterococcal BT-BSI were (several patients received combination empirical treatment) piperacillin-tazobactam (30 patients), meropenem (20), linezolid (9), ciprofloxacin or levofloxacin, vancomycin and cephalosporins (7 each), daptomycin and metronidazole (5 each), teicoplanin, amoxicillin-clavulanic acid and imipenem (3), and aztreonam, gentamicin, ampicillin and colistin (1 each).

**DISCUSSION**

In this study, the prevalence, features, outcomes, and risk factors for BT-BSI due to *E. faecalis* or *E. faecium* were described; the independent risk factors associated with this etiology were cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous use of carbapenem and chronic kidney disease. Also, a predictive score with moderate prediction ability was developed.

Inappropriate empirical therapy has been associated with increased mortality in some studies of BT-BSI, and isolation of enterococci is related to inappropriate therapy, as was the case in this study; therefore, providing information about when these organisms should be covered empirically is relevant (5, 8). Many of the antibiotics recommended in guidelines for biliary tract infections are not active against enterococci (i.e., cephalosporins, aztreonam, and some of the carbapenems in the case of *E. faecalis*; or all beta-lactams in most of cases of *E. faecium*). Addition of vancomycin is recommended in all health care-associated infections in the Tokyo and IDSA guideline (6, 7); this would have mean treating with vancomycin 379 (46.8%) of the BT-BSI episodes in our cohort (i.e., all nosocomial and health care-associated cases), of which only 51 (13.4%) had enterococci isolated in blood cultures. The Tokyo guidelines also recommended vancomycin for grade III cases; we did not use that severity scale, but considering those with sepsis or shock as a proxy, 122 episodes with community-acquired BT-BSI who presented with sepsis or shock would have also needed to be treated with vancomycin, of which only 9 (7.4%) were caused by enterococci. Therefore, the sensitivity and specificity of the criteria recommended in the Tokyo guidelines for covering enterococci in our cohort was 38.4% and 71.3%, respectively, with a positive predictive value of 11.2% and negative predictive value of 92.5%.

To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score. The small number of cases did not allow us to perform an internal validation; although the predictive score developed needs external validation and showed a moderate predictive ability, it may be of help in the decision to cover enterococci in patients with biliary tract infections. The limited discriminative ability of our score may be due to the high rate of polymicrobial BSI cases since it raised significantly when applied to monomicrobial episodes and particularly those caused by *E. faecium*. In addition, we analyzed *E. faecium* and *E. faecalis* together but the risk factor for BSI due to these organisms may not be the same (9).

In patients with a biliary tract sepsis, empirical coverage against Gram-negative bacteria is mandatory in all cases. We think that patients with a score ≤ 6 and without

### TABLE 4 Outcomes of patients with biliary tract bloodstream infections according to isolation of *Enterococcus faecalis* and *Enterococcus faecium*

| Variables                  | All patients (\( n = 850 \)) (%) | Isolation of *E. faecalis* or *E. faecium* (\( n = 73 \)) | No isolation others (\( n = 777 \)) | \( P \) value |
|----------------------------|-----------------------------------|---------------------------------------------------------|-------------------------------------|---------------|
| Inappropriate empirical therapy | 209 (24.5)                       | 32 (43.8)                                               | 177 (22.8)                           | 0.0002        |
| 30-day mortality           | 128 (15.1)                       | 16 (21.9)                                               | 112 (14.4)                           | 0.087         |
| Persistent fever           | 97 (11.4)                        | 11 (15.1)                                               | 86 (11.1)                            | 0.30          |
| Persistent bacteremia      | 18 (2.1)                         | 4 (5.5)                                                 | 14 (1.8)                             | 0.061         |
| Relapse                    | 44 (5.2)                         | 8 (11.0)                                                | 36 (4.6)                             | 0.020         |
| Secondary infection\(^a\) | 10 (1.2)                         | 3 (4.1)                                                 | 7 (0.9)                              | 0.047         |

\(^a\)Endovascular or orthopedic device infections.
septic shock may be safely treated empirically without coverage against enterococci. On the other hand, coverage for *Enterococcus* spp. should be considered in patients with a score ≥10. In patients with a score between 7 and 9, the need to cover enterococci should be evaluated considering the severity of infection and other generic risk factors for enterococcal bacteremia regardless the source beyond the specific variables included in the score (i.e., immunosuppression, other types of cancer, previous use of other broad-spectrum antimicrobials) (9).

In our analysis, the presence of cholangiocarcinoma increased the risk for enterococci by 4.5-fold. In a prospective observational study, including 173 episodes of bacteremic cholangitis, *E. faecium* was the third most frequent bacteria isolated on blood cultures in patients with solid tumors (and mainly hepato-biliary-pancreatic cancer) (2). Also, bile duct colonization by *E. faecium* has been shown to be associated with infection in patients with perihilar cholangiocarcinoma (10, 11). The association of biliary stents with *Enterococcus* spp. infection has been previously shown (12, 13); *Enterococcus* spp. bacteremia in cholangitis episodes is more frequent when a biliary endoprosthesis is present (12). Chronic kidney disease has been described as a risk factor for enterococcal BSI in several studies, even if not focusing on BT-BSI (12, 13). Finally, the use of carbapenems is a well-recognized risk factors for enterococcal bacteremia, and particularly for *E. faecium* (14–16).

This study has several limitations. First, the number of enterococcal BT-BSI included might have limited the statistical power to find some risk factors. Second, we did not collect specific data on the different type of biliary tract infections. Third, the results are not applicable to BT infections without bacteremia. And fourth, the predictive score was not externally validated. Some strengths include the prospective nature of the study and the multicenter representation.

In conclusion, we found some specific risk factors for enterococcal BT-BSI and derived a predictive score that might be useful for guiding decisions about coverage of these organisms, pending its validation in external cohorts.

**MATERIALS AND METHODS**

**Design, setting, and patients.** This is a post hoc analysis of the PROBAC project, a prospective, observational, multicenter cohort study, including consecutive patients with bloodstream infections (BSI) admitted to 26 Spanish hospitals from October 2016 to March 2017; the design and inclusion criteria have been described elsewhere (8, 17).

For this sub-analysis, patients in the PROBAC cohort for whom the biliary tract was considered to be the source of BSI (BT-BSI) were eligible. The biliary tract was considered the source of the BSI on the basis of clinical and radiologic data, including right upper quadrant pain, jaundice, elevated bilirubin levels and radiological signs of cholecystitis or biliary tract obstruction; the microorganisms isolated in bile or surgical samples were checked when available but only for confirmation of the source of bacteremia (patients without bacteremia were not included). Both polymicrobial and monomicrobial bloodstream infections were included. Blood cultures were obtained, processed, and interpreted in accordance with standard recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology (18).

**Variables and definition.** BT-BSI were classified into those caused by *E. faecalis* or *E. faecium* and those caused by other pathogens. Episodes caused by species of enterococci different from *E. faecalis* or *E. faecium* were excluded from the analyses because of their very low numbers and potentially different epidemiological and clinical implications. Despite not all species of enterococci were analyzed, from now on we will refer to enterococci or *Enterococcus* spp. for the ease of understanding.

The variables collected included: demographics, underlying conditions and their severity, exposure to invasive procedures and devices during the previous week, type of acquisition (community, health care-associated or nosocomial), acute severity of disease, immunosuppressive therapy and previous antimicrobial use. The severity of underlying conditions was assessed using the age-adjusted Charlson comorbidity index (19). Neutropenia was defined as moderate (<500 neutrophils/μL) and severe (<100 neutrophils/μL). Liver diseases were classified as moderate or severe when the patient presented a B or C class according to Child-Pugh classification (20). Presentation with sepsis or shock was considered according to Sepsis 3 criteria (21, 22). The Sequential Organ Failure Assessment (SOFA) score (23) at presentation and Pitt score (24) 1 day before were also measured. Chronic kidney disease was defined moderate to severe according to the Charlson Comorbidity index parameter (19). Infections were classified as hospital acquired (HA), health care associated (HCA) or community-acquired accordingly to Friedman et al. (25). Immunosuppressive therapy included cancer chemotherapy or radiotherapy, typical immunosuppressants, and steroids if dosing used was >10 mg/day of prednisone or equivalent for more than 3 weeks.

Outcome variables included inappropriate empirical treatment (i.e., lack of use of *in vitro* active drugs before the susceptibility of blood pathogens isolated was known), 30-day mortality, relapse (reappearance
of bacteremia after documentation of negative blood cultures or clinical improvement and completion of active antimicrobial therapy), persistent fever (longer than 72 h in patients treated with an in vitro active antimicrobial regimen), persistent bacteremia (isolation of the same bacteria in follow-up blood cultures after 72 h of active antimicrobial regimen), and secondary endovascular or orthopedic devices infection.

**Statistical analysis.** To analyze the risk factors for enterococcal etiology, exposure to the different variables were compared between patients with and without isolation of enterococci in blood cultures using the Chi-square test and Fisher exact test for categorical variables, and the T-Student test and Mann-Whitney U for continuous variables, as appropriate. Stratified analyses were performed whenever necessary to understand the correlation among variables.

Among the possible variables associated with *Enterococcus* spp., those clinically meaningful and with a univariate P value <0.1 were included in a multivariate logistic regression model. The variables selection was performed using a manual stepwise backward process, including potential interactions. The predictive ability of the final models for observed data were evaluated by calculating their area under the receiver operating characteristic curve (AUROC) with 95% confidence interval (CI).

A predictive score was developed using the final multivariate model. The value of the predictors included in the score was calculated by dividing each beta coefficient by half of the smallest one and rounding to the nearest unit. The positive predictive value (PPV), negative predictive value (NPV), sensitivity and specificity of the score were calculated. Statistical analysis was carried out with the Statistical Package for the Social Sciences version 18.0 (SPSS Inc., Chicago, IL, USA).

**Ethical approval.** The PROBAC project was approved by the Ethics Committee of Hospital Universitario Virgen Macarena. Approval was also obtained at each participating center according to local requirements. The need to obtain written informed consent was waived because of the observational nature of the study.

**ACKNOWLEDGMENTS**

Other members of the PROBAC REIPI/GEIH-SEIMC/SAEI Group: Joaquín Lanz-García (Hospital Universitario Virgen Macarena, Sevilla), Miguel Montejo (Hospital Universitario de Cruces, Bilbao), María Teresa Pérez-Rodríguez (Hospital Universitario de Vigo, Vigo), Enrique Corzo-Delgado (Hospital Universitario de Valme, Sevilla), Carmen Fariñas (Hospital Universitario Marqués de Valdecilla, Santander), Marta Arias-Temprano (Hospital Universitario de León, León), Jonathan Fernández-Suárez (Hospital Universitario Central de Asturias, Oviedo), Juan Manuel Sánchez-Calvo (Hospital de Jerez de la Frontera, Jerez de la Frontera), Jordi Cuquet-Pedragosa (Hospital General Granollers, Granollers), Andrés Martin-Aspas (Hospital Universitario Puerta del Mar, Cádiz), Isabel Gea-Lázaro (Hospitalario Ciudad de Jaén, Jaén), Marcos Guzmán García (Hospital San Juan de la Cruz, Úbeda), Jesús Canueto Quintero (Hospital Punta de Europa, Algeciras), Isabel María Reche (Complejo Hospitalario Torrecárdenas, Almería), Inés Pérez-Camacho (Hospital de Poniente, Almería), Esperanza Merino de Lucas (Hospital General Universitario de Alicante, Valencia), Clara Natera Kindelán (Hospital Universitario Reina Sofía), I.E.L.C. has served as scientific advisor for Angelini, ViIV, Gilead and Correvio, and has served as trainer for ViIV. P.R.G. has served as scientific advisor for Shionogi, speaker for MSD, Pfizer, and Gilead and has served as trainer for MSD. A.S. received honoraria from MSD and Pfizer for accredited educational activities and has served as speaker for Pfizer. F.G.S. has served as a speaker for Pfizer and Astellas. The other authors report no conflicts of interest relevant to this article.

This work was financed by Plan Nacional de I+D+i 2013-2016, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades, through grants PI16/01432 and Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001; RD16/0016/0007; and RD16/0016/0012); co-financed by European Development Regional Fund “A Way to Achieve Europe,” Operative program Intelligent Growth 2014–2020.

**REFERENCES**

1. Tan M, Jensen TG, Nielsen SL, Schaffalitzky de Muckadell OB, Laursen SB. 2021. Analysis of patterns of bacteremia and 30-day mortality in patients with acute cholangitis over a 25-year period. Scand J Gastroenterol 56. https://doi.org/10.1080/00365521.2021.1902558.

2. Royo-Cebrecos C, Gudiel C, García J, Tubau F, Laporte J, Ardanyu C, Antonio M, Marin M, Gornals JB, Carratalá J. 2017. Characteristics, aetiology, antimicrobial resistance and outcomes of bacteremic cholangitis in patients with solid tumours: a prospective cohort study. J Infect 74: 172–178. https://doi.org/10.1016/j.jinf.2016.10.008.

3. Melzer M, Toner R, Lacey S, Bettany E, Rait G. 2007. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. Postgrad Med J 83:773–776. https://doi.org/10.1136/pgmj.2007.064683.

4. Tagashira Y, Sakamoto N, Isogai T, Hikone M, Kosaka A, Chino R, Higuchi M, Uehara Y, Honda H. 2017. Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteremic cholangitis: a retrospective cohort study. Clin Microbiol Infect 23:740–747. https://doi.org/10.1016/j.cmi.2017.02.027.
Predictive Score for BSI Due to Enterococcus spp.

Microbiology Spectrum